- Home
- ARQT vs CBZ Comparison
ARQT vs CBZ Comparison
Compare ARQT & CBZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQT | CBZ |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.7B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ARQT | CBZ |
|---|---|---|
| Price | $28.33 | $52.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $24.83 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 725.5K |
| Earning Date | 10-28-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.66 |
| Revenue | $317,929,000.00 | ★ $2,675,607,000.00 |
| Revenue This Year | $85.51 | $55.67 |
| Revenue Next Year | $30.74 | $6.13 |
| P/E Ratio | ★ N/A | $31.57 |
| Revenue Growth | ★ 129.21 | 59.19 |
| 52 Week Low | $11.13 | $47.89 |
| 52 Week High | $31.77 | $90.13 |
Technical Indicators
Market Signals| Indicator | ARQT | CBZ |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 50.34 |
| Support Level | $27.55 | $49.89 |
| Resistance Level | $28.90 | $54.50 |
| Average True Range (ATR) | 1.15 | 1.88 |
| MACD | -0.55 | 0.21 |
| Stochastic Oscillator | 18.58 | 58.30 |
Price Performance
Historical ComparisonAbout ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About CBZ CBIZ Inc.
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the majority of its revenues from the Financial Services segment and geographically from the United States.